Research

Hormonal

Tirzepatide does not demonstrate a disproportionate risk of gynecological hemorrhagic events compared to semaglutide in real-world post-marketing surveillance.

If you are using tirzepatide and experience menstrual changes, know that current large-scale data shows your risk of bleeding is statistically similar to those using semaglutide. High consumer reporting on social media may inflate the perception of risk, but clinical evidence does not support a unique safety signal for tirzepatide regarding gynecological hemorrhage.

ModerateRefutesMEDIUM confidence
This analysis of post-marketing surveillance data did not detect a disproportionate reporting signal suggesting an increased risk of gynecological hemorrhagic events with tirzepatide compared to semaglutide.
Hima Bindu Makkena · Cureus · 2026

Why this rating

The study uses a large real-world pharmacovigilance dataset (FAERS) with concurrent timeframes, but relies on spontaneous reporting which is subject to bias and lacks denominator data.

Source

Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022–2025)

Hima Bindu Makkena · Cureus · 2026

DOI 10.7759/cureus.101738

cohort · n=103607
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →